Future long-term studies of patients who presented COVID-19 should include analysis of persistent membrane expression of IL-22R1 and plasma concentrations of IL-22BP as they could represent predictors of persistent inflammation and/or malignancy development. This evidence concerns the gene IL22RA1 and COVID-19.